Newron regains safinamide rights from Merck Serono

10/24/2011 | InPharm.com

Merck Serono returned rights to safinamide, an experimental Parkinson's disease medicine, to Newron Pharmaceuticals. Safinamide has "a more limited market potential than originally anticipated," said Merck Serono. The firms will continue working on another Parkinson's drug candidate, sarizotan, and insomnia treatment pruvanserin.

View Full Article in:

InPharm.com

Published in Brief: